For Alzheimer’s Patient, Hope Renewed Following Biogen Announcement
By
Tanner Jensen
| December 6th, 2019
When biotechnology company Biogen announced the cancellation of the trial for their Alzheimer’s drug aducanumab, nearly 3,500 trial participants were left in limbo. Now,…
Follow us